Other

Nederlandse Organisatie Voor Toegepast-natuurwetenschappelijk Onderzoek

Louis Hartog Cohen

Gijsbert Arie Van Der Marel

Jacobus Hubertus Van Boom

Mark Overhand

Elsbet Jantine Pieterman

Willem Ferdinand Nieuwenhuizen

Hans Van Den Elst

Nicolaas Johannes Meeuwenoord

Steven Hendrik Leonard Verhelst

Nicolette Voskuyl

Herman Steven Overkleeft

Brigitte Elisa Anna Burm

Adrianus Petrus Valentijn

Novel peptide-like FPP-analogues suitable for inhibiting protein:prenyl transferases, such as protein:geranylgeranyl transferase-1, and other prenyl pyrophosphate-consuming enzymes such as squalene synthase and geranylgeranyl pyrophosphate synthase are disclosed.

Inhibitors of prenylated pyrophosphate consuming enzymes

Protein:prenyl transferase inhibitors

The invention provides an immobilised oligopeptide for detecting protein prenylation consisting of an oligopeptide containing the amino acid sequence Xad-Xac-Xab-Xaa-OH at its carboxyl-terminus, at least one of Xaa, Xab, Xac and Xad representing cysteine (Cys), said sequence being capable of acting as a substrate for a prenyl transferase catalysing protein prenylation, and being bonded to a solid carrier, preferably at its amino-terminus. The invention further provides a kit for detecting protein prenylation comprising a first immobilised oligopeptide as mentioned above and a second immobilised oligopeptide which differs from said first immobilised oligopeptide in that the cysteine residue is substituted by another amino acid. Also provided are antibodies against the prenylated oligopeptides.

Reagent and kit for determining isoprenylating activity and inhibition

The invention provides a method for inhibiting protein isoprenylation by administration of a polyisoprenyl pyrophosphate analogue. The polyisoprenyl pyrophosphate analogue may have formula 1, ##STR1## wherein: Pren represents a C.sub.10 -C.sub.30 terpenoid group or a derivative thereof; A.sup.1, A.sup.2, A.sup.3 and A.sup.4 independently represent a direct bond or a C.sub.1 -C.sub.4 alkylene or alkenylene group, optionally having substituents selected from methyl, hydroxy, methoxy, mercapto, methylthio, amino, methylamino, dimethylamino, halogen and a group having formula --X.sup.5 --A.sup.5 --P(.dbd.Z.sup.2)Y.sup.2 Y.sup.3 ; A.sup.5 represents a direct bond or a C.sub.1 -C.sub.4 alkylene or alkenylene group; X.sup.1, X.sup.2, X.sup.3, X.sup.4 and X.sup.5 independently represent a direct bond, oxygen, sulphur, imino or methylimino; Y.sup.1, Y.sup.2 and Y.sup.3 independently represent hydroxy, alkoxy, mercapto, alkylthio, amino, mono- or di-alkylamino, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or arylalkyl, whereby one of Y.sup.1, Y.sup.2 and Y.sup.3 may also represent a C.sub.7 -C.sub.30 alkyl or alkenyl group or a group having formula --X.sup.5 --A.sup.5 --P(.dbd.Z.sup.2)Y.sup.2 Y.sup.3 and two of Y.sup.1, Y.sup.2 and Y.sup.3 may together represent an oxygen or sulfur atom or an imino or methylene group; Z.sup.1 and Z.sup.2 independently represent oxygen or sulphur; and n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition containing such a polyisoprenyl pyrophosphate analogue, which composition is suitable for the treatment of carcinomas such as by the inhibition of the isoprenylation of a member of the ras protein family.

Method for the treatment of diseases related with protein isoprenylation

Growing community of inventors

Breukelen, Netherlands

Louis Hartog Cohen